GlaxoSmithKline Consumer Healthcare Limited has declared its financial results for the second quarter ended September 30, 2018. The Revenue for the company recorded a growth of 14.4%. The quarter reported revenue of Rs. 1,272 crore, while the PBT was at Rs. 427 crores, a growth of 43%. The quarter witnessed a strong double-digit volume growth at 13.7% that is broad based and cuts across portfolio and channels.
Company’s e-commerce channel continues to grow at an accelerated pace, delivering a healthy growth rate. Rural channel and Modern Trade continued to grow with rural reaching out to over 22,000 villages.
Commenting on the results, Navneet Saluja, Managing Director, GlaxoSmithKline Consumer Healthcare Limited said, “Our financial performance in the last quarter reflects our commitment towards developing products based on high science. With initiatives and campaigns such as Horlicks Swasthyan Abhiyaan, Horlicks restage, and launch of Boost “Play the Pros”, we have strengthened our engagement with consumers”.
“We will continue to drive innovation across our products and campaigns, which will strengthen the trust in our consumers. This in turn will foster further growth in our financial performance and help us maintain leadership in the HFD category”. Mr. Saluja added.
- Health food drink portfolio continues to be the market leader with 64.2% value share**
- Base Horlicks witnessed a strong double-digit volume growth
- Our access agenda continues to gain strength with our HFD distribution reaching 1.81MN in Q2
- Focused and customised campaigns such as Horlicks Swasthyan Abhiyaan, Horlicks restage, and Boost “Play the Pros” touched the relevant audience group which in turn contributed to our HFD portfolio growth